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Navneet S. Majhail, MD, MS,1,2 Nancy A. Omondi, MBA, MS,3 Ellen Denzen, MS,3
Elizabeth A. Murphy, EdD, RN,3 J. Douglas Rizzo, MD, MS4,5Hematopoietic cell transplantation (HCT) is a highly specialized and resource-intense medical procedure
that can be associated with disparities in access to transplantation. Barriers to access to HCTare multifac-
torial, complex, and interrelated. Our current knowledge of specific barriers that prevent access to HCT is
very limited. As the utilization of HCT increases, it is imperative that underserved populations receive the
benefit of this life-saving procedure. We review the prevailing literature on access to HCT and describe
research priorities for eliminating disparities in transplantation. Better understanding of these complex bar-
riers will minimize inequities, inform health policy, guide development of interventions targeted to eliminate
disparities, and continue the expansion of HCT in the future.
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Underserved populationsINTRODUCTION
Hematopoietic cell transplantation (HCT) is cura-
tive therapy for a various malignant and nonmalignant
hematologic disorders. The use of HCT has increased
progressively over the last 4 decades since reports of
first successful transplantations in 1968. An estimated
50,000 transplants are performed worldwide each
year, including 20,000 in the United States [1]. With
emerging indications, improvements in technology
and supportive care, and increasing availability of
alternative graft sources and reduced-intensity condi-
tioning regimens, the use of HCT can be expected to
increase further in the future. However, HCT is
a highly specialized, technologically sophisticated,
resource-intense, and expensive procedure that can1Center for International Blood and Marrow Transplant
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These health care disparities have clinical, ethical,
and policy implications. Here we review the available
literature on access to HCT and describe barriers
that need to be addressed to ensure equitable access
to HCT for all segments of the population.ACCESS TO CANCER CARE
Access to health care has been defined as ‘‘the
timely use of affordable personal health services to
achieve the best possible health outcomes’’ [2,3]. Man-
delblatt et al. [3] very elegantly summarized the
complexities of access to health care: ‘‘The process of
gaining access to care represents dynamic interactions
of diverse individuals in their social context interfacing
with health care providers, who, in turn, are operating
in a variety of changing and often constrained medical
care structures and environments.’’ Disparities exist in
the health care of minority populations in the United
States; compared with the majority population, minor-
ities do not have the same access to health care and as
a result do not receive the same quality of health care
and have poorer overall health status [4-6]. The Insti-
tute of Medicine’s reportUnequal Treatment: Confront-
ing Racial and Ethnic Disparities in Healthcare concluded
that even when other health care access–related factors
(eg, ability to pay for care) are the same, racial and eth-
nic minorities receive lower-quality health care than
whites [5]. The report recommended a comprehensive,
multilevel strategy to eliminate these disparities,
Figure 1. Potential barriers to access to HCT.
Biol Blood Marrow Transplant 16:1070-1075, 2010 1071Access to HCTincluding increasing awareness among providers,
patients, payors, health plan purchasers, and society
at large; enhancing training and education; and
conducting research on interventions.
Cancer care is associated with disparities in detec-
tion, treatment, and outcomes for specific high-risk
populations. These high-risk populations include
elderly patients, women, patients of black or Hispanic
race/ethnicity, underinsured or uninsured persons,
patients from lower socioeconomic strata, patients
with lower levels of health literacy and education,
and patients living in rural areas [3,7-11]. The origins
of these inequities are multifactorial and complex.
Patient barriers include demographics, language, ac-
culturation, attitudes, and family and cultural contexts
[3]. In addition, health care providers play an impor-
tant role in ensuring access to cancer care. Physician-
and provider-specific barriers that have been reported
in the literature include age and race biases, biases and
beliefs about screening and treatment efficacy, defi-
cient knowledge and training, lack of confidence,
lack of culturally sensitive resources, lack of time, con-
cerns about patient acceptance, cost concerns, and
logistic and organizational barriers [2,12-15]. Finally,
health care system barriers, such as organizational
and structural factors and reimbursement and financial
forces, can facilitate or hinder access to optimal cancer
care [3]. Factors can also be closely interrelated; for
instance, racial and ethnic minorities are more likely
to be uninsured compared to whites [16].ACCESS TO HCT
HCT is most commonly performed for malignant
hematologic disorders, and barriers that prevent access
to cancer care alsomaybe relevant forHCT.Additional
barriers may have a role as well, becauseHCT is a high-
cost and sophisticated medical procedure that involves
complex interactions among patient, provider, and
health care system factors (Figure 1).
The available literature on access to HCT is very
limited (Table 1). Previous studies generally have
had insufficient statistical power to detect differences
among access indicators and/or frequently have used
databases with limited applicability to exploring access
issues, particularly their causes. For example, inpatient
hospital discharge databases may not be truly appropri-
ate for health disparities research, because they may not
capture the universe of patients with hematologicmalig-
nancies or who underwent transplantation in a popula-
tion cohort. In addition, the disease and procedure
codes used to identify patients from these data sets
lack precision, and important prognostic factors, such
as disease stage and remission status, which could affect
decisionmaking regarding the use ofHCT, could not be
considered in these analyses. Furthermore, contempora-neous studies are lacking, and the majority of previous
studies addressed barriers in an era when present-day
transplantation techniques were not widely available.
Possible limitations in study design notwithstand-
ing, previous studies have increased our understanding
of barriers that limit access to transplantation. For
instance, current literature highlights substantial
geographic variation in access to HCT. Mitchell
et al. [17], in a study using hospital discharge data
from 4 states (California, Massachusetts, Maryland,
and New York) for the years 1988 and 1991, found be-
tween-state differences in access to HCT by insurance
coverage and race. Compared with patients with pri-
vate insurance, Medicaid beneficiaries in California,
New York, and Maryland/Massachusetts were 78%,
64%, and 61% as likely to undergo transplantation
for leukemia and 69%, 56%, and 32% as likely to
receive a transplant for lymphoma, respectively. Simi-
larly, compared with whites, Hispanics were signifi-
cantly less likely to undergo transplantation for
lymphoma in New York, but had similar rates of
transplantation for lymphoma in California and for
leukemia in all 4 states.
Specific disparities to access to HCT that have
been identified in the literature include age, sex, race,
insurance status, and other barriers.Age
Studies that have investigated age as a predictor of
access to HCT have found that younger patients are
more likely to receive a transplant than older patients.
Mitchell et al. [17] showed that each 10-year increase
in age was associated with a 10%-18% (variation by
state) lower likelihood of undergoing HCT for leuke-
mia or lymphoma. In a study using inpatient discharge
data from Texas for the year 1999, Hwang et al. [18]
reported that elderly patients (aged $65 years) had
a significantly lower likelihood of receiving a transplant
for leukemia with each year increase in age; however,
no age effect was noted among pediatric (aged \18
years) and adult (aged18-64 years) recipients. In a study
Table 1. Access to HCT: Summary of Published Studies
Reference Access Focus Data Sources Study Design n Population Characteristics Results
Mitchell et al. [17] Age, sex, race, education,
insurance
Inpatient hospital discharge
data for California,
Maryland, Massachusetts,
and New York
ICD-9 codes used to identify
inpatients with leukemia or
lymphoma and recipients
of auto-HCTor allo-HCT
in 1988 and 1991
38,420 inpatients with
leukemia or lymphoma;
1655 HCT recipients
 AML, 13%; ALL, 15%; CML,
6%; NHL, 45%
 Whites, 72%; Blacks, 9%
 Blue Cross, 53%; Medicaid,
18%; HMO, 12%
 Blacks and older patients
less likely to receive HCT.
 Patients with private
insurance more likely to
receive HCT.
Mehta et al. [20] Sex SEER, IBMTR SEER incidence rates and data
from IBMTR used to
estimate rates of allo-HCT
for AML, ALL, and CML
from 1989-1999*
18,932 patients with AML,
ALL, or CML; 13,083 HCT
recipients
AML, 24%; ALL, 22%; CML,
54%
No sex differences in allo-
HCTutilization.
Hwang et al. [18] Age, sex, race,
insurance, comorbidities
Texas inpatient hospital
discharge data
ICD-9 codes used to identify
inpatients with acute or
chronic leukemias and
recipients of auto-HCTor
allo-HCT
in 1999
6574 inpatients with
leukemia;
1604 HCT recipients
 AML, 27%; ALL, 24%; CML,
13%; CLL, 31%
 Whites, 70%; Blacks, 8%
 Medicare/Medicaid, 50%;
commercial payer, 30%
 Elderly ($65 years)
women less likely to
receive HCT.
 No impact of payor status
and ethnicity on HCT
utilization.
Cho [19],† Age, sex, race, insurance,
center factors,
comorbidities
Arizona inpatient hospital
discharge data
ICD-9 codes used to identify
inpatients with leukemia or
lymphoma and recipients
of auto-HCTor allo-HCT
from 1997-2003
6435 inpatients with leukemia
or lymphoma; 207 HCT
recipients
 AML, 14%; ALL, 17%; NHL,
43%
 Private payer, 35%; HMO,
32%; Medicare/Medicaid,
24%
 Patients with private
insurance more likely to
receive HCT.
 No impact of sex and race
on HCTutilization.
Joshua et al. [21] Sex, race SEER, US Census Bureau, and
CIBMTR
SEER incidence rates and data
from CIBMTR used to
estimate rates of auto-
HCTand allo-HCT for
leukemia, lymphoma, and
myeloma from
1997-2002
273,853 patients with
leukemia, lymphoma, or
myeloma; 45,750 HCT
recipients
 AML, 21%; ALL, 9%; CML,
11%; NHL, 21%; MM, 40%
 Whites, 90%; Blacks, 10%
 Blacks less likely to receive
auto-HCTor allo-HCT.
 Women less likely to
receive auto-HCT.
ICD indicates International Classification of Diseases; IBMTR, International Bone Marrow Transplant Registry (now CIBMTR); AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic
myelogenous leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma.
*HCT reported to IBMTR from 1989-1992 and SEER incidence estimates from 1992-1999 were used for this analysis.
†Non–peer-reviewed manuscript.
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Biol Blood Marrow Transplant 16:1070-1075, 2010 1073Access to HCTusing Arizona hospital discharge data from 1997-2003,
Cho [19] reported that increasing age reduces the
probability of undergoing transplantation for leuke-
mia; the study found no effect of age on the likelihood
of undergoing transplantation for lymphoma. These
previous studies predate the advent of reduced-
intensity and nonmyeloablative preparative regimens,
which are associated with lower risks of morbidity
and mortality and now make transplantation a viable
treatment option for many older patients. Additional
factors may have an impact on the use of HCT in older
patients. Older patients may decline or their providers
may not recommend an aggressive therapy such as
HCT. Also, some differences in transplantation use
among older patients may be appropriate, because
older patients may have comorbidities and disease
characteristics that may make them ineligible for
transplantation; no previous study has been able to suf-
ficiently account for these important variables.
Sex
Mitchell et al. [17] andCho [19] found no impact of
sex on the likelihood of transplantation for leukemia or
lymphoma.Hwang et al. [18] reported that elderlymen
were more likely to undergo transplantation for leuke-
mia than elderly women, but they found no effect of sex
on pediatric and adult HCT recipients. In a study that
specifically attempted to address the issue of sex and ac-
cess to HCT, Mehta et al. [20] used 1989-1999 data
from the International Bone Marrow Transplant Reg-
istry (IBMTR) and Surveillance Epidemiology and
End Results (SEER) database. They concluded that
there was no significant bias toward the use of HCT
in males compared with females. However, in a more
recent large study that used data from the Center for
International Blood and Marrow Transplant Research
(CIBMTR) and SEER, Joshua et al. [21] showed that
men were more likely to undergo HCT than women;
this difference was seen in autologous HCT for lym-
phoma or myeloma, but not in allogeneic HCT. The
reasons for sex-specific disparities, if any, are unclear
and should be explored in future studies.
Race
The role of race in access to HCT must be inter-
preted with caution. Race is a complex social, cultural,
and political construct, not a biological concept; ac-
cordingly, the definition of race has changed and
evolved over time. Self-reported race is most accurate,
but race is assigned by centers or providers in numer-
ous databases. In one of the earliest studies of access to
HCT, Mitchell et al. [17] showed that blacks were less
likely than whites to undergo HCT for leukemia or
lymphoma in each of the 4 states investigated. Joshua
et al. [21] reported that the likelihood of undergoing
HCT for leukemia, lymphoma, and multiple myelomais significantly lower for blacks than for whites, and
that these differences existed for autologous, matched
sibling donor, and unrelated donor HCT. In contrast,
Hwang et al. [18] and Cho [19] found no impact of race
on transplantation rates.
Insurance Status
HCT is a costly procedure [22,23], and patients
with no or limited health insurance coverage may have
a lower likelihood of receiving HCT. Three previous
studies have addressed the impact of insurance coverage
on access to HCT. Mitchell et al. [17] reported that
Medicaid patients, self-paying (ie, uninsured) patients,
and Health Maintenance Organization (HMO) enroll-
ees with leukemia or lymphoma were significantly less
likely to undergo HCT compared with patients with
private insurance. The authors suggested that the lower
probability of undergoing HCT among HMO enroll-
ees could be related to coverage restrictions or delays
in gaining approval for costly medical procedures such
as HCT. Cho [19] also reported that patients with
less-generous insurance coverage were less likely to un-
dergo HCT for leukemia and lymphoma. However,
Hwang et al. [18] found no association between payor
status (commercial insurance,HMO,Medicare,Medic-
aid, self-pay, and other payor) and receipt of HCT for
leukemia. These findings were specific to the state of
Texas, and the authors noted that the lack of relation-
ship between payor status and HCT use could be
from equitable access toHCTor the study’s lack of sta-
tistical power to identify significant associations. The
interaction of insurance status with other sociodemo-
graphic factors has not yet been explored. For example,
children may have greater access to HCT compared
with adults because of the presence of hospital, state,
or federal programs that provide coverage for HCT.
Other Barriers
Education status, estimated by zip code of resi-
dence, was not identified as a major factor associated
with access toHCTbyMitchell et al. [17]. Cho [19] ex-
amined the association between hospital characteristics
and likelihood of undergoing HCT for leukemia in
Arizona. Patients with leukemia and lymphoma admit-
ted to minor teaching hospitals (vs major teaching
hospitals) and small- or medium-sized hospitals (vs
large hospitals [.250 beds]) were less likely to undergo
HCT.Patients admitted to for-profithospitals andgov-
ernment-owned hospitals had comparable probabilities
of undergoing HCT.AREAS FOR FURTHER RESEARCH
Research is needed to further characterize dispar-
ities in access toHCT, identify causes for anydisparities
deemed inappropriate, and investigate interventions to
1074 Biol Blood Marrow Transplant 16:1070-1075, 2010N. S. Majhail et al.mitigate those barriers. Researchondisparities in access
to HCT can be challenging, however. Typically, a very
large population cohort must be assembled for any
study of access to health care. Reliable estimates of the
numerator (eg, numberof transplantations for a disease)
and denominator (eg, total number of patients with that
disease for whom transplantation is appropriate) for
a cohort over a given time period are needed as well.
Finally, comprehensive information about the factors
possibly associated with disparate access (eg, race and
ethnicity, education status, socioeconomic status, cul-
tural attitudes, insurance/payment status) is required.
Large administrative databases, such as the SEER-
Medicaredata set, are frequentlyused to identify dispar-
ities in access to cancer care. Because these large
databases cannot robustly collect information about ac-
cess indicators, surrogate variables are used to evaluate
barriers that might affect access to treatment (eg, zip
code to assign socioeconomic status, education status,
and place of residence). The majority of federal and
claims databases do not contain robust information
about hematologic malignancies and HCT, and details
of important prognostic factors (eg, cytogenetic risk)
that predict which patients should be considered
for HCT generally are not available. However, good-
quality studies using administrative and claims data-
bases may be possible in the near future because of
enhanced data collection efforts by multiple groups.
For example, SEER has collected data on myelodys-
plastic syndrome and chronic myeloproliferative disor-
ders since 2001. Since 2007, all allogeneic HCTs in the
United States are to be reported to theCIBMTRunder
the requirements of the StemCell Therapeutic andRe-
search Act of 2005.
Database studies can be useful for identifying some
aspects of health care disparities; however, they are
not optimal for evaluating individual patient- and
provider-level barriers or to identify the causes of
disparate access. Additional health services research
methodologies (eg, patient and physician surveys, qual-
itative research methods, such as focus groups) are
needed to better understand obstacles to universal ac-
cess to HCT and also account for inherent inequities
in access toHCTresulting frombiological andmedical
factors. For instance, ethnic and racial minorities have
a lower probability of finding a suitable donor and have
a higher prevalence of comorbidities, which may make
them ineligible for transplantation [24-26]. Once etiol-
ogies of disparate access have been characterized, stud-
ies evaluating targeted interventions to address barriers
to access are needed as well.
For underserved populations to obtain the benefit of
a life-saving procedure such asHCT, it is imperative that
the medical community work to reduce inappropriate
disparities and ensure equitable access to transplantation.
Our current knowledge about specific barriers that pro-
hibit access to HCT is limited. While waiting for betterinformation, the medical community, including payors,
policy makers, and health care providers, must use the
current awareness of disparate access as a call to action
to examine their own practices and work to eliminate in-
appropriate disparities. A better understanding of these
complex barriers will minimize inequities, inform health
policy, guide development of interventions targeted to
eliminate disparities, and contribute to the expansion
of HCT in the future.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. PasquiniMC,WangZ, SchneiderL.Current use andoutcomeof
hematopoietic stem cell transplantation, part I: CIBMTR sum-
mary slides, 2007. CIBMTR Newsletter. 2007;13:5-9. Available
at: http://www.cibmtr.org/PUBLICATIONS/Newsletter/index.
html. Accessed August 1, 2009.
2. Millman M. Access to Health Care in America. Washingon, DC:
National Academy Press; 1993.
3. Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to can-
cer services: a review of barriers to quality care. Cancer. 1999;86:
2378-2390.
4. Groman R, Ginsburg J. Racial and ethnic disparities in health
care: a position paper of the American College of Physicians.
Ann Intern Med. 2004;141:226-232.
5. Institute of Medicine. Unequal Treatment: Confronting Racial and
Ethnic Disparities in Healthcare. Washington, DC: National
Academy Press; 2003.
6. Agency for Healthcare Research and Quality. 2008 National
Healthcare Quality Report. Rockville, MD: US Department of
Health and Human Services; 2009.
7. Shavers VL, Brown ML. Racial and ethnic disparities in the
receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334-357.
8. WardE, Jemal A, CokkinidesV, et al. Cancer disparities by race/
ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:
78-93.
9. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the
United States by education level and race. J Natl Cancer Inst.
2007;99:1384-1394.
10. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US
whites andminorities: a SEER (Surveillance, Epidemiology, and
End Results) Program population-based study. Arch Intern Med.
2002;162:1985-1993.
11. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeco-
nomic status on cancer incidence and stage at diagnosis: selected
findings from the surveillance, epidemiology, and end results:
National Longitudinal Mortality Study. Cancer Causes Control.
2009;20:417-435.
12. Haggerty J, Tudiver F, Brown JB, et al. Patients’ anxiety and
expectations: how they influence family physicians’ decisions toor-
der cancer screening tests. Can Fam Physician. 2005;51:1658-1659.
13. Tudiver F, Guibert R, Haggerty J, et al. What influences family
physicians’ cancer screening decisions when practice guidelines
are unclear or conflicting? [Abstract]. J Fam Pract. 2002;51:760.
14. Battista RN,Williams JI, MacFarlane LA. Determinants of pri-
mary medical practice in adult cancer prevention. Med Care.
1986;24:216-224.
15. Battista RN,Williams JI, MacFarlane LA. Determinants of pre-
ventive practices in fee-for-service primary care. Am J PrevMed.
1990;6:6-11.
16. Ward E, Halpern M, Schrag N, et al. Association of insurance
with cancer care utilization and outcomes. CA Cancer J Clin.
2008;58:9-31.
Biol Blood Marrow Transplant 16:1070-1075, 2010 1075Access to HCT17. Mitchell JM, Meehan KR, Kong J, et al. Access to bone
marrow transplantation for leukemia and lymphoma: the
role of sociodemographic factors. J Clin Oncol. 1997;15:
2644-2651.
18. Hwang JP, Lam TP, Cohen DS, et al. Hematopoietic stem cell
transplantation among patients with leukemia of all ages in
Texas. Cancer. 2004;101:2230-2238.
19. Cho C. Factors affecting stem cell transplantation for leukemia
and lymphoma. Available at: http://hdl.handle.net/1961/3595.
Accessed August 1, 2009.
20. Mehta P, Pollock BH,NugentM, et al. Access to stem cell trans-
plantation: do women fare as well as men? Am J Hematol. 2003;
72:99-102.
21. Joshua TV, Rizzo JD, Zhang MJ, et al. Access to hematopoietic
stem cell transplantation: effect of race and gender [Abstract].
Biol Blood Marrow Transplant. 2007;13(Suppl):22.22. Majhail NS,Mothukuri JM, Brunstein CG, et al. Costs of hema-
topoietic cell transplantation: comparison of umbilical cord
blood andmatched related donor transplantation and the impact
of post-transplant complications. Biol Blood Marrow Transplant.
2009;15:564-573.
23. Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hema-
topoietic cell transplantation with high-dose regimens.Biol Blood
Marrow Transplant. 2008;14:197-207.
24. Bonow RO, Grant AO, Jacobs AK. The cardiovascular state of
the union: confronting healthcare disparities. Circulation. 2005;
111:1205-1207.
25. KollmanC,WeisT, SwitzerGE, et al.Non-HLAbarriers to un-
related donor stem cell transplantation. BoneMarrow Transplant.
2001;27:581-587.
26. NorrisK,NissensonAR.Race, gender, and socioeconomicdisparities
in CKD in the United States. J Am Soc Nephrol. 2008;19:1261-1270.
